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Abstract
In a pilot study designed as a case control study the effi-
cacy of donepezil treatment was investigated in patients
with Alzheimer’s disease (AD). Patients were stratified
according to radiological criteria into patients without
(AD group) and with subcortical vascular lesions
(AD+SVD group). Changes in cognition were assessed as
the primary outcome measurement after 6 and 18
months of treatment by the Mini-Mental Status Examina-
tion (MMSE) and the Consortium to Establish a Registry
for Alzheimer’s Disease (CERAD) test battery. After 6
months, patients had improved from baseline by 0.7
points in MMSE score in the AD group and by 1.8 in the
AD+SVD group. After 18 months of treatment, the
AD+SVD group performed significantly worse in one
CERAD subscore, whereas a deterioration in two sub-
scores was observed in the AD group. A comparison
between the 2 groups revealed that treatment did not
lead to statistically significant differences between the
AD and AD+SVD groups in any of CERAD parameters fol-
lowing 6 or 18 months of treatment. These data support
previous observations that donepezil therapy is effective
in AD patients with and without subcortical vascular
lesions.
Copyright © 2004 S. Karger AG, Basel
Introduction
Several studies have suggested that at least a third of
Alzheimer disease (AD) subjects bear a significant cere-
brovascular pathology [1, 2]. Differentiation between AD
and AD with subcortical vascular lesions (AD+SVD) may
have important clinical implications. The presence of
subcortical infarctions and ischemic white matter lesions
is an important distinguishing factor in routine clinical
diagnostics for probable AD.
Donepezil was approved for the treatment of patients
with mild to moderate AD in autumn 2000. In our outpa-
tient group, a considerable number of patients were radio-
logically diagnosed as having vascular lesions, mostly as
white matter lesions, in addition to other radiological
signs indicative for AD. At the beginning of this pilot
study there were no reports available investigating wheth-
er cholinesterase inhibitors are effective in AD patients
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with cerebrovascular lesions. In the meantime several
studies have shown that cholinesterase inhibitors may be
effective in the treatment of AD and vascular dementia
[3–6].
In the present pilot study, we investigated whether AD
patients with and without white matter lesions are differ-
ent with regard to their clinical outcome. As primary out-
come, we used the relative changes in Mini-Mental Status
Examination (MMSE) and the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) test battery.
Thus, the pilot study will reveal whether donepezil is
effective in AD patients with white matter lesions. The
German version of the CERAD test battery was normal-
ized using a large group of healthy controls. The CERAD
test battery has not yet been applied in other studies on
vascular or mixed dementia, therefore this study will also
evaluate its usefulness in AD drug studies.
Subjects and Methods
Study Design and Protocol
A case control, pilot study was conducted on outpatients. Patients
were assessed by standardized diagnostic procedures including neuro-
logical, psychiatric and general medical examination. All subjects
underwent laboratory tests to exclude secondary causes of dementia.
Additional studies including a cerebrospinal fluid analysis and elec-
troencephalogram were performed as the clinical situation indicated.
Afterwards the AD patients were stratified according to magnetic
resonance imaging criteria into 2 groups. The first group had no
radiological signs of subcortical vascular pathology other than those
also found in healthy, age-matched controls. The second group exhib-
ited lacunar lesions, predominately white matter lesions. The white
matter lesions were unitary or bilaterally distributed throughout cere-
bral white matter. Punctate white matter lesions and confluent white
matter abnormalities were observed. The white matter lacunar
infarcts were presented in white (70% of all) and in both subcortical
grey and white brain matter (30%).
Patients were excluded from participating in the study if they had
evidence of degenerative neurological disorders other than AD, espe-
cially when there was evidence for multi-infarct dementia. The
patient and caregiver provided written informed consent prior to the
study. This study was conducted in accordance with the Declaration
of Helsinki and its subsequent amendments [7].
Efficacy Measures
A trained and blinded neuropsychologist administered a stan-
dard battery of neuropsychological tests. The severity of disease was
assessed at baseline by Clinical Dementia Rating [8] and the CERAD
battery, described in detail elsewhere [9–13]. CERAD could be com-
pleted by all patients. This CERAD battery consists of 5 tests: Verbal
Fluency: Animal Category, a short form of the Boston Naming Test,
MMSE [14], Verbal Memory Test (VMT) consisting of word list
learning with immediate (sum of 3 trials), delayed recall and a recog-
nition procedure and Constructional Practice (including delayed
recall).
Fig. 1. The calculations of CERAD cognitive battery in the z-scores
in the AD+SVD (a) and AD (b) groups. Bars represent means of z-
score values from 10 patients for the group at baseline, 6 months and
18 months. The z-score values of all cognitive tests of both groups are
below the mean of the normative population (defined as 0) and are
therefore expressed in negative values. The narrative of data at the x
axis are depicted as follows: 1 = Verbal Fluency; 2 = Boston Naming
Test; 3 = MMSE; 4 = Verbal Memory Test (VMT) immediate recall;
5 = VMT delayed recall; 6 = Constructional Practice total sum;
7 = Constructional Practice delayed recall. * p ! 0.05 in ANOVA
analysis.
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Table 1. Baseline characteristics of AD and
AD+SVD patients AD AD+SVD
Patients 10 10
Females 6 7
Age (mean B SEM) 71B2.4 (56–79) 81B2.4 (64–92)
Education, years (mean B SEM, range) 9.3B1.2 9.5B0.7
61 APOE-Â4 allele, patients 5 6
MMSE (mean B SEM) 19.7B1.9 21.5B1.3
Clinical dementia rating scores 11.0 10 10
Risk factors
Hypertension 4 5
Smoking (past or present) 1 2
Diabetes 1 2
Hypercholesterolemia 8 6
Hypertriglyceridemia 4 4
Comorbidity
Angina pectoris, coronary artery disease 1 4
Focal neurological signs 0 4
Peripheral vascular disease 0 1
160% stenosis of ACI 0 0
Arteriosclerotic plaques in ACI 5 9
SEM = Standard error of the mean; ACI = arteria carotis interna.
Table 2. Concomitant medication (number of patients)
AD AD+SVD
Antithrombotic agents 4 6
Aspirin 4 6
Vitamins 0 2
Analgesics (including NSAIDs) 0 3
Antihypertensive drugs 5 6
Serum lipid reducing agents 3 2
Antipsychotics 2 3
Antidepressive therapy 4 5
Treatment
Initially, all enrolled patients received open-label donepezil 5 mg
once daily. After 1 month, the dose was increased to 10 mg once daily
for 18 months based on the clinicians’ judgment of tolerability and
efficacy. Psychometric evaluations took place during clinic visits at
baseline and at 6 and 18 months.
Data Analysis
Data are expressed as z scores of the normative sample of 1,100
cognitively healthy persons (fig. 1) [13]. Z scores represent the stan-
dard deviation of a single person’s cognitive scoring in comparison to
the median of the normative sample defined as 0. In order to com-
pare the AD plus AD+SVD groups to the normative population,
standard deviation values were used. A difference of !1 standard
deviation was considered to be a normal variation from the control
value. Statistical analysis was performed first by comparing the cog-
nitive scoring of both groups at baseline, and at 6 and 18 months by
multiple comparisons using the ANOVA test.
Results
Patients’ Characteristics
The baseline characteristics of the AD and AD+SVD
groups are presented in table 1. The AD+SVD group
exhibited a higher prevalence of vascular comorbidities
(table 1, 2).
Clinical Efficacy of Treatment with Donepezil in AD
and AD+SVD Groups
The baseline values in CERAD tests of the AD and
AD+SVD groups were calculated in z scores and the mean
values of 10 patients at each investigated time point are
demonstrated in figure 1. At baseline, all z-score values
were !1 standard deviation except for Boston Naming
(fig. 1a, b). Baseline values were not statistically different
between the 2 groups as calculated by the Mann-Whitney
test. Patients of both groups were treated with a dosage of
10 mg donepezil for at least 18 months. During this peri-
od, no patient had to be excluded from the study because
of side effects or other serious adverse events. Following 6
months of treatment, AD+SVD patients showed a trend
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Fig. 2. a The time course of mean MMSE scores B standard error of
the mean are shown; n = 10 for each group. * p ! 0.05 when com-
pared to baseline. b The time course for geriatric depression scale
(GDS) during the study period, n = 10 for each group (mean B
SEM).
to improvement in all 7 scores of the CERAD battery
(fig. 1a).
In contrast, the AD group showed a trend to improve-
ment in only 1 parameter (fig. 1b). Only VMT immediate
recall statistically differed between both groups at this
time point. After 18 months of treatment the AD+SVD
group performed even better in two CERAD items where-
as in the AD group one CERAD subscore was improved.
Comparing the relative changes between the groups, no
statistical differences were detected for any parameter
after 18 months of treatment.
In the AD+SVD group, a significant improvement in
MMSE score was observed after 6 months of donepezil
treatment (21.5 B 1.3 versus 23.3 B 1.3; mean B SEM),
and was below baseline levels after 18 months (20.6 B
1.5; fig. 2a). In the AD group, the comparative analysis to
baseline revealed a nonsignificant improvement in
MMSE score after 6 months (19.7 B 1.9 versus 20.4 B
2.0) and a statistically significant deterioration after 18
months of treatment (17.2 B 2.7; p ! 0.05 compared to
baseline; fig. 2a).
The Trail-Making test (TMT) part B was not com-
pleted by all patients, therefore only TMT part A was
evaluated. The time to perform the TMT part A increased
by 146% in the AD group and by 183% in the AD+SVD
group.
In our cohort, as assessed in the geriatric depression
scale, both groups suffered from mild depression, e.g. 13.2
in AD versus 10.9 points in AD+SVD group (fig. 2b).
Both groups were almost equally treated with antidepres-
sive drugs (table 2) and they improved after 6 months to
8.5 points in AD versus 9.0 points in the AD+SVD
group.
Discussion
In this prospective study, AD patients with and with-
out subcortical vascular lesions were treated with donepe-
zil for 18 months. A deterioration in MMSE was observed
when compared to baseline. In comparison to previous
placebo studies, the degree of cognitive decline was clearly
less in both treatment groups [15].
There is strong evidence that donepezil causes a slow-
ing in disease progression in both groups since different
cognitive domains did not change during the course of the
disease. In the present study, for example, the degree of
impairment in delayed recall was similar between base-
line and after 18 months of treatment.
A significant worsening was observed for verbal fluen-
cy in the AD group whereas in the AD+SVD group only a
trend to a worsening was observed. This coincides with
the observation of Schmidtke and Hull [16] who found an
inferior performance in verbal fluency in AD patients.
The VMT immediate recall (recognition memory) was
previously shown to be better preserved in AD patients
with subcortical ischemic vascular dementia [17].
In our study, although both patient groups were similar
in their z scores for VMT-recognition at baseline and after
18 months of treatment, after 6 months of treatment the
AD+CVD group statistically improved in comparison to
the AD group. The observed congruence in VMT imme-
diate recall could, however, be due to bias from the small
patient cohort or differences in the type of vascular patho-
logies.
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In some studies, donepezil was shown to be effective in
vascular dementia [3–6]. However, in most of these stud-
ies, the exclusion criteria did not account for the heteroge-
neity of vascular dementia. There is considerable varia-
tion concerning the vascular pathology in AD due to dif-
ferences in imaging techniques, rating scales, cutoff points
in lesion severity grading and study populations.
This study is in line with other reports suggesting that
cholinesterase inhibitors are effective for the treatment of
AD patients with a significant subcortical vascular pathol-
ogy. It also indicates that the cholinergic system is
affected in these patients. The cholinergic deficit is well
established for AD [18], but considerably less for patients
with vascular comorbidity.
Summarizing, the group of patients with AD+SVD
had a clear benefit from donepezil treatment. Therefore,
this group of patients should not be excluded from treat-
ment with cholinesterase inhibitors due to their vascular
comorbidities. In contrast, this group of patients may
even have a stronger profit than patients with AD pathol-
ogy only.
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